HC Wainwright reissued their buy rating on shares of Arvinas (NASDAQ:ARVN - Free Report) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $81.00 price objective on the stock.
A number of other research firms have also issued reports on ARVN. Stifel Nicolaus reduced their price objective on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a research report on Wednesday, February 12th. Oppenheimer downgraded shares of Arvinas from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 11th. Bank of America lowered their price target on shares of Arvinas from $54.00 to $28.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. Finally, BMO Capital Markets set a $20.00 target price on shares of Arvinas and gave the stock an "outperform" rating in a research report on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.53.
Check Out Our Latest Stock Analysis on ARVN
Arvinas Stock Up 5.0 %
ARVN stock traded up $0.33 during trading on Monday, hitting $6.95. 2,851,035 shares of the company's stock traded hands, compared to its average volume of 1,085,943. The stock has a market capitalization of $477.97 million, a price-to-earnings ratio of -2.51 and a beta of 2.30. Arvinas has a 52 week low of $5.94 and a 52 week high of $38.56. The stock has a fifty day moving average price of $12.58 and a two-hundred day moving average price of $19.18.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the business earned ($2.53) EPS. As a group, equities research analysts expect that Arvinas will post -3.81 EPS for the current fiscal year.
Insider Transactions at Arvinas
In other news, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the transaction, the chief executive officer now owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. The trade was a 2.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Noah Berkowitz sold 8,658 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the sale, the insider now directly owns 110,023 shares of the company's stock, valued at approximately $945,097.57. This represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,230 shares of company stock valued at $769,402. Corporate insiders own 5.23% of the company's stock.
Institutional Investors Weigh In On Arvinas
Several large investors have recently modified their holdings of ARVN. GF Fund Management CO. LTD. purchased a new stake in shares of Arvinas during the fourth quarter valued at $28,000. KBC Group NV lifted its stake in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after buying an additional 1,255 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Arvinas during the fourth quarter valued at about $171,000. Tema Etfs LLC acquired a new position in shares of Arvinas in the fourth quarter worth about $227,000. Finally, Teacher Retirement System of Texas increased its position in shares of Arvinas by 19.0% in the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock worth $274,000 after acquiring an additional 2,280 shares in the last quarter. 95.19% of the stock is owned by institutional investors.
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Featured Stories
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
